Mesenchymal stromal cells (MSCs) are adult, multipotent stem cells of mesodermal origin.
In addition to their stem cell properties, MSCs possess broad immunosuppressive functions
influencing both adaptive and innate immune effector cells (IECs). This anti-inflammatory
potential is triggered by the release of inflammatory cytokines produced by immune
cells in the microenvironment. Indeed, high levels of inflammatory cytokines induce
MSCs to become immunosuppressive (primed-MSCs). The immunosuppressive potential of
primed-MSCs results from a dynamic interaction between MSCs and IECs mediated by the
release of bioactive factors, including extracellular vesicles (EVs). EVs are secreted
by many cell types and influence various biological processes, both directly activating
cell surface receptors through bioactive ligands and delivering transcription factors,
oncogenes, mRNA, and non-coding regulatory RNAs, such as microRNAs (miRNA), into target
cells. In this study, we have investigated the undisclosed molecular mechanisms regulating
the immunosuppressive capabilities of EVs derived from primed-MSCs (primed-EVs), starting
from a molecular characterization of their contents by high-throughput approaches.
We analyzed miRNAs, mRNAs and proteins differentially expressed in primed-EVs compared
to ctrl-EVs. We found miR-155-5p and miR-6723-5p significantly up-regulated in primed-EVs.
Enrichment analysis on predicted target genes revealed an involvement of miR-155-5p
and miR-6723-5p in different pathways regulating immunomodulatory processes. Moreover,
we found IDO mRNA significantly up-regulated in primed-EVs. Furthermore, primed-EVs
showed 73 proteins significantly modulated compared to ctrl-EVs. Enrichment analysis
on modulated proteins revealed different pathways up and down regulated involved in
immunomodulatory properties exerted by primed-EVs. This molecular characterization
of MSC-EVs, and the consequent functional validation of candidate molecules, will
pave the way for novel therapeutic perspectives for the treatment of inflammatory
and autoimmune diseases.
To read this article in full you will need to make a payment